Patents by Inventor Michael D. Bartberger

Michael D. Bartberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PRMT5 inhibitors and uses thereof
    Patent number: 12583859
    Abstract: The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: March 24, 2026
    Assignees: California Institute of Technology, 1200 Pharma LLC, The Regents of the University of California
    Inventors: Brendan M. O'Boyle, Corey M. Reeves, Justin A. Hilf, Brian M. Stoltz, Michael D. Bartberger, Steven J. Wittenberger, Oliver C. Loson, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
    Publication number: 20260078091
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: March 4, 2025
    Publication date: March 19, 2026
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • CDK inhibitors and uses thereof
    Patent number: 12486280
    Abstract: The present disclosure provides compounds and compositions that are CDK inhibitors selective for CDK4 and/or CDK6, and methods of use thereof.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: December 2, 2025
    Assignees: California Institute of Technology, The Regents of the University of California, 1200 Pharma LLC
    Inventors: Brendan M. O'Boyle, Justin A. Hilf, Scott C. Virgil, Alexander W. Sun, Brian M. Stoltz, Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Michael D. Bartberger
  • ERK inhibitors and uses thereof
    Patent number: 12428416
    Abstract: The present disclosure provides compounds and compositions that are inhibitors of ERK1, ERK2, or both, and methods of use thereof.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 30, 2025
    Assignees: California Institute of Technology, 1200 Pharma LLC, The Regents of the University of California
    Inventors: Corey M. Reeves, Brendan M. O'Boyle, Justin A. Hilf, Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Steven J. Wittenberger, Oliver C. Loson, Michael D. Bartberger, Brian M. Stoltz
  • SELECT KRAS G12C INHIBITORS AND USES THEREOF
    Publication number: 20250136582
    Abstract: The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. Certain compounds described herein are unexpectedly potent and more effective in inhibiting cancer cell proliferation that is driven, at least in part, by KRAS protein with a G12C mutation. Certain compounds are exceptionally suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation, and the potency of the compounds offer certain advantages to effect therapeutic benefit.
    Type: Application
    Filed: November 9, 2022
    Publication date: May 1, 2025
    Inventors: Tristin E. Rose, Brendan M. O'Boyle, Justin A. Hilf, Zhengao Feng, Michael D. Bartberger, Brian M. Stoltz, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon, Emma L. Baker-Tripp
  • Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
    Publication number: 20240300892
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: October 11, 2023
    Publication date: September 12, 2024
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • MCL1 INHIBITORS AND USES THEREOF
    Publication number: 20230116602
    Abstract: The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.
    Type: Application
    Filed: October 2, 2020
    Publication date: April 13, 2023
    Inventors: Brendan M. O' Boyle, Emma L. Baker-Tripp, Corey M. Reeves, Kevin C. Yang, Tristin E. Rose, Justin A. Hilf, Brian M. Stoltz, Michael D. Bartberger, Oliver C. Loson, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
    Patent number: 11407721
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 9, 2022
    Assignee: AMGEN INC.
    Inventors: Michael D. Bartberger, Hilary Plake Beck, Michael R. Degraffenreid, Brian M. Fox, Felix Gonzalez Lopez De Turiso, Lisa D. Julian, Frank Kayser, Julio C. Medina, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xuelei Yan
  • KRAS G12C INHIBITORS AND USES THEREOF
    Publication number: 20220227738
    Abstract: The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.
    Type: Application
    Filed: May 20, 2020
    Publication date: July 21, 2022
    Inventors: Justin A. Hilf, Tristin E Rose, Michael D. Bartberger, Brendan M. O'Boyle, Corey M. Reeves, Oliver C. Loson, Brian M. Stoltz, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20220194949
    Abstract: The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.
    Type: Application
    Filed: March 25, 2020
    Publication date: June 23, 2022
    Inventors: Brendan M. O'Boyle, Corey M. Reeves, Justin A. Hilf, Brian M. Stoltz, Michael D. Bartberger, Steven J. Wittenberger, Oliver C. Loson, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
    Publication number: 20220169611
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 2, 2022
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Dequette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua Ma, Lawrence R. McGee, Josel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • Benzimidazole derivatives and their uses
    Patent number: 11332459
    Abstract: The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: May 17, 2022
    Assignee: TEIJIN PHARMA LIMITED
    Inventors: Michael D. Bartberger, Nagasree Chakka, Hua Gao, Angel Guzman-Perez, Daniel B. Horne, Zihao Hua, Madeleine Kieffer, Daniel C. H. Lin, Benjamin Charles Milgram, Jane Panteleev, Laurie Schenkel, John Stellwagen, Matthew Weiss, Ryan D. White, Wei Zhao
  • CDK INHIBITORS AND USES THEREOF
    Publication number: 20220106325
    Abstract: The present disclosure provides compounds and compositions that are CDK inhibitors selective for CDK4 and/or CDK6, and methods of use thereof.
    Type: Application
    Filed: July 26, 2019
    Publication date: April 7, 2022
    Inventors: Brendan M. O'Boyle, Justin A. Hilf, Scott C. Virgil, Alexander W. Sun, Brian M. Stoltz, Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Michael D. Bartberger
  • ERK INHIBITORS AND USES THEREOF
    Publication number: 20220002294
    Abstract: The present disclosure provides compounds and compositions that are inhibitors of ERK1, ERK2, or both, and methods of use thereof.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 6, 2022
    Inventors: Corey M. Reeves, Brandan M. O'Boyle, Justin A. Hilf, Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Steven J. Wittenberger, Oliver C. Loson, Michael D. Bartberger, Brian M. Stoltz
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11096939
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: August 24, 2021
    Assignee: Amgen Inc.
    Inventors: Shon Booker, John Gordon Allen, Brian Alan Lanman, Ryan Paul Wurz, Ning Chen, Victor J. Cee, Patricia Lopez, Aaron C. Siegmund, Michael D. Bartberger
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11045484
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: June 29, 2021
    Assignee: Amgen Inc.
    Inventors: Ryan Paul Wurz, Victor J. Cee, Albert Amegadzie, Ning Chen, Brian Alan Lanman, Michael D. Bartberger
  • Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
    Publication number: 20210179560
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: August 3, 2020
    Publication date: June 17, 2021
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 10988485
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: April 27, 2021
    Assignee: Amgen Inc.
    Inventors: Ana Elena Minatti, Jonathan Dante Low, Ryan Paul Wurz, Brian Alan Lanman, Victor J. Cee, Michael D. Bartberger, Margaret Chu-Moyer
  • BENZIMIDAZOLE DERIVATIVES AND THEIR USES
    Publication number: 20200308145
    Abstract: The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: October 18, 2018
    Publication date: October 1, 2020
    Applicant: Amgen Inc.
    Inventors: Michael D. BARTBERGER, Nagasree CHAKKA, Hua GAO, Angel GUZMAN-PEREZ, Daniel B. HORNE, Zihao HUA, Madeleine KIEFFER, Daniel C. H. Lin, Benjamin Charles MILGRAM, Jane PANTELEEV, Laurie SCHENKEL, John STELLWAGEN, Matthew WEISS, Ryan D. WHITE, Wei ZHAO
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20200030324
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: May 31, 2019
    Publication date: January 30, 2020
    Inventors: Shon BOOKER, John Gordon ALLEN, Brian Alan LANMAN, Ryan Paul WURZ, Ning CHEN, Victor J. CEE, Patricia LOPEZ, Aaron C. SIEGMUND, Michael D. BARTBERGER